SNRPA抗体—艾普蒂

The SNRPA antibody targets the Small Nuclear Ribonucleoprotein Polypeptide A (SNRPA), a core component of the U1 small nuclear ribonucleoprotein (snRNP) complex involved in pre-mRNA splicing. SNRPA, also known as U1-A, binds specifically to U1 snRNA, facilitating spliceosome assembly and recognition of 5' splice sites during RNA processing. This protein plays a critical role in maintaining splicing accuracy and regulating gene expression. Antibodies against SNRPA are primarily used in research to study spliceosome dynamics, RNA-protein interactions, and splicing mechanisms in cellular models. Clinically, anti-SNRPA autoantibodies are associated with autoimmune disorders, particularly systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD), where they serve as diagnostic biomarkers. Their presence often correlates with specific disease manifestations, such as Raynaud's phenomenon or neurological involvement. Studies using SNRPA antibodies have also explored links between splicing dysregulation and cancers or neurodegenerative diseases. These antibodies are typically validated via techniques like Western blotting, immunofluorescence, and immunoprecipitation, with careful optimization required due to potential cross-reactivity with related snRNP proteins. Ongoing research focuses on elucidating SNRPA's role in disease pathogenesis and its potential as a therapeutic target.